NEXGEL Secures Financing for $16.6M Conditional Acquisition

LANGHORNE, Pa. – February 10, 2026 – NEXGEL, Inc. (NASDAQ: NXGL), a specialist in advanced hydrogel products, today announced it has secured initial financing of $1.797 million for a potential acquisition targeted to close in the first quarter of 2026. The deal signals a significant step in the company's aggressive growth strategy, with a potential additional investment of $14.869 million hinging on the successful outcome of a comprehensive due diligence process.

The announcement underscores a pivotal moment for the Pennsylvania-based company, known for its healthcare, beauty, and over-the-counter (OTC) products. While the identity of the acquisition target remains confidential, the structure of the deal—particularly its conditionality—offers a transparent look into the high-stakes world of corporate mergers and acquisitions. If the transaction is not ultimately consummated, the initial funds will be returned to the undisclosed investor, a clause that highlights the critical nature of the forthcoming evaluation period.

A Strategy of Deliberate Growth

This potential acquisition is not an isolated event but rather the latest move in a carefully orchestrated expansion strategy. NEXGEL has built a reputation for growing its portfolio through targeted acquisitions that create tangible synergies. In a statement, CEO Adam Levy referenced this history, noting, “After successfully closing and integrating several acquisitions over the last several years, we have continued to evaluate other potential accretive transactions.”

This track record provides a blueprint for what the company likely hopes to achieve. In December 2023, NEXGEL acquired Kenkoderm, a direct-to-consumer (DTC) brand focused on psoriasis care, which expanded its footprint in the specialized skincare market. This was followed by the May 2024 acquisition of Silly George, an eye and lash beauty brand. The Silly George deal proved particularly synergistic, as NEXGEL leveraged its core hydrogel technology to introduce new under-eye patch products to the brand's established DTC customer base. Post-acquisition, Silly George's annual revenue run rate reportedly grew from $2 million to over $5 million, demonstrating NEXGEL's ability to integrate and scale new assets.

This pattern suggests the current target will likely complement NEXGEL’s existing infrastructure, whether by providing access to new consumer markets, adding established brands to its portfolio, or offering new channels for its proprietary hydrogel technology. The focus remains on accretive transactions—deals that are expected to increase the company’s earnings per share—and further solidify its market position.

The Due Diligence Gauntlet

While the strategic intent is clear, the deal's future rests entirely on the due diligence process. The two-tiered financing structure—an initial $1.797 million followed by a potential $14.869 million—is designed to facilitate this crucial phase. The initial funds allow for a deep dive into the target's operations, financials, and legal standing before the larger investment is committed.

The “funds returned” clause is a significant feature, effectively creating an escape hatch that protects the investor if the target company fails to meet expectations. For NEXGEL, it means the pressure is on to ensure the identified assets can withstand intense scrutiny. This process in the healthcare and consumer goods sectors is notoriously complex, involving a meticulous review of intellectual property rights, regulatory compliance with bodies like the FDA, product liability risks, manufacturing processes, and the stability of supply chains.

“We have identified assets to acquire with an up-front commitment from an investor,” Levy stated, emphasizing that the larger investment is “pending the completion of full due diligence by both parties and subject to other conditions.” The involvement of Palladium Capital Group, LLC as the placement agent for the financing adds a layer of institutional credibility to the transaction, but it does not remove the inherent risks.

Reshaping the Consumer Landscape

Beyond the financial metrics, the acquisition holds the potential to reshape product offerings in the consumer health and beauty spaces. NEXGEL's core competency lies in its electron-beam, cross-linked hydrogels, which are prized for being ultra-gentle and having a high water content. These properties make them ideal for a range of applications, from advanced wound care with its SilverSeal® brand to consumer beauty products.

Should the acquisition proceed, NEXGEL could infuse its advanced hydrogel science into a new set of products, creating innovative solutions and a distinct competitive advantage. For example, acquiring a brand with a strong presence in dermatology could lead to new hydrogel-based delivery systems for active ingredients. Similarly, a deal in the broader consumer wellness space could open doors for new types of cooling patches, beauty masks, or other OTC remedies.

This strategy of leveraging a core technology across a diversified portfolio of brands is a powerful engine for growth. It allows the company to innovate from its scientific base while acquiring brands that already possess market recognition and distribution channels, thereby accelerating the path from lab to consumer shelf.

Investor Outlook and Market Context

This announcement arrives at an interesting time for NEXGEL. Despite reporting robust revenue growth of 36.9% over the past three years, the company's stock (NASDAQ: NXGL) was trading near a five-year low as of the announcement date. This disconnect suggests that while the company has been growing operationally, it has yet to fully capture investor confidence. A successful, large-scale acquisition could be the catalyst needed to change that narrative.

Historically, the market has responded constructively to NEXGEL's M&A activities. The Silly George acquisition, for instance, was met with a modest but positive stock price gain, as investors recognized the potential for revenue growth and synergy. The current deal, with its much larger potential value, will be watched even more closely.

Shareholders and the broader market must now wait for further details, which CEO Adam Levy promised to provide during the first quarter of 2026. Until then, the transaction remains a compelling but uncertain prospect, a forward-looking ambition subject to the rigorous, and often unpredictable, realities of corporate due diligence.